Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review.

Sara Madaschi, Alessandro Rossini, Ilaria Formenti, Vito Lampasona, Stefania Bianchi Marzoli, Gabriella Cammarata, Letterio S. Politi, Vittorio Martinelli, Elena Bazzigaluppi, Marina Scavini, Emanuele Bosi, Roberto Lanzi

Research output: Contribution to journalArticle

Abstract

To report the use of rituximab to treat thyroid-associated orbitopathy (TAO) in a patient with a concomitant B-cell organ-specific autoimmune disorder-the stiff person syndrome (SPS). We present a case report and a review of the related literature. A 62-year-old man with SPS, latent autoimmune diabetes of the adult, and Graves-Basedow disease was referred to our medical center because of bilateral TAO. An ophthalmologic examination documented asymmetric bilateral NOSPECS (N = no signs or symptoms; O = only signs, no symptoms; S = soft tissue involvement; P = proptosis; E = extraocular muscle involvement; C = corneal involvement; and S = sight loss) class IV TAO (left eye>right eye) with a clinical activity score of 5 on a scale of 7. Magnetic resonance imaging of the orbits documented bilateral exophthalmos (left eye>right eye) due to retrobulbar fibroadipose infiltration, bilateral increase of extrinsic ocular muscle thickness, and enhancement of the left inferior rectus muscle on T2-weighted sequences. Because of concomitant incapacitating SPS and diet-controlled latent autoimmune diabetes of the adult, we excluded long-term corticosteroid therapy as an option and considered the use of rituximab, a mouse-human chimeric monoclonal antibody targeting the CD20 protein on pre-B and mature B lymphocytes. Rituximab was administered in accordance with the protocol for rheumatoid arthritis. During the subsequent 4 months, clinical signs and symptoms of TAO dramatically resolved (clinical activity score = 0 of 7) with a sustained improvement of the spastic paraparesis. The glutamic acid decarboxylase antibody titer remained high, and glycemic control and first-phase insulin secretion did not change. Treatment of active TAO with rituximab should be considered when standard intravenous pulse glucocorticoid treatment is contraindicated or ineffective and when SPS or other organ-specific autoimmune disorders with involvement of humoral autoimmunity are present, inasmuch as more than 1 disease may benefit from the use of this chimeric monoclonal antibody.

Original languageEnglish
Pages (from-to)677-685
Number of pages9
JournalEndocrine Practice
Volume16
Issue number4
Publication statusPublished - Jul 2010

Fingerprint

Stiff-Person Syndrome
Thyroid Gland
Signs and Symptoms
Exophthalmos
Graves Disease
Oculomotor Muscles
B-Lymphocytes
Monoclonal Antibodies
Spastic Paraparesis
Therapeutics
Muscles
Glutamate Decarboxylase
Orbit
Protein Transport
Autoimmunity
Glucocorticoids
Rheumatoid Arthritis
Adrenal Cortex Hormones
Magnetic Resonance Imaging
Rituximab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease : case report and literature review. / Madaschi, Sara; Rossini, Alessandro; Formenti, Ilaria; Lampasona, Vito; Marzoli, Stefania Bianchi; Cammarata, Gabriella; Politi, Letterio S.; Martinelli, Vittorio; Bazzigaluppi, Elena; Scavini, Marina; Bosi, Emanuele; Lanzi, Roberto.

In: Endocrine Practice, Vol. 16, No. 4, 07.2010, p. 677-685.

Research output: Contribution to journalArticle

@article{8c624c1d3d07410eba297dadd59c7d63,
title = "Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review.",
abstract = "To report the use of rituximab to treat thyroid-associated orbitopathy (TAO) in a patient with a concomitant B-cell organ-specific autoimmune disorder-the stiff person syndrome (SPS). We present a case report and a review of the related literature. A 62-year-old man with SPS, latent autoimmune diabetes of the adult, and Graves-Basedow disease was referred to our medical center because of bilateral TAO. An ophthalmologic examination documented asymmetric bilateral NOSPECS (N = no signs or symptoms; O = only signs, no symptoms; S = soft tissue involvement; P = proptosis; E = extraocular muscle involvement; C = corneal involvement; and S = sight loss) class IV TAO (left eye>right eye) with a clinical activity score of 5 on a scale of 7. Magnetic resonance imaging of the orbits documented bilateral exophthalmos (left eye>right eye) due to retrobulbar fibroadipose infiltration, bilateral increase of extrinsic ocular muscle thickness, and enhancement of the left inferior rectus muscle on T2-weighted sequences. Because of concomitant incapacitating SPS and diet-controlled latent autoimmune diabetes of the adult, we excluded long-term corticosteroid therapy as an option and considered the use of rituximab, a mouse-human chimeric monoclonal antibody targeting the CD20 protein on pre-B and mature B lymphocytes. Rituximab was administered in accordance with the protocol for rheumatoid arthritis. During the subsequent 4 months, clinical signs and symptoms of TAO dramatically resolved (clinical activity score = 0 of 7) with a sustained improvement of the spastic paraparesis. The glutamic acid decarboxylase antibody titer remained high, and glycemic control and first-phase insulin secretion did not change. Treatment of active TAO with rituximab should be considered when standard intravenous pulse glucocorticoid treatment is contraindicated or ineffective and when SPS or other organ-specific autoimmune disorders with involvement of humoral autoimmunity are present, inasmuch as more than 1 disease may benefit from the use of this chimeric monoclonal antibody.",
author = "Sara Madaschi and Alessandro Rossini and Ilaria Formenti and Vito Lampasona and Marzoli, {Stefania Bianchi} and Gabriella Cammarata and Politi, {Letterio S.} and Vittorio Martinelli and Elena Bazzigaluppi and Marina Scavini and Emanuele Bosi and Roberto Lanzi",
year = "2010",
month = "7",
language = "English",
volume = "16",
pages = "677--685",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "4",

}

TY - JOUR

T1 - Treatment of thyroid-associated orbitopathy with rituximab--a novel therapy for an old disease

T2 - case report and literature review.

AU - Madaschi, Sara

AU - Rossini, Alessandro

AU - Formenti, Ilaria

AU - Lampasona, Vito

AU - Marzoli, Stefania Bianchi

AU - Cammarata, Gabriella

AU - Politi, Letterio S.

AU - Martinelli, Vittorio

AU - Bazzigaluppi, Elena

AU - Scavini, Marina

AU - Bosi, Emanuele

AU - Lanzi, Roberto

PY - 2010/7

Y1 - 2010/7

N2 - To report the use of rituximab to treat thyroid-associated orbitopathy (TAO) in a patient with a concomitant B-cell organ-specific autoimmune disorder-the stiff person syndrome (SPS). We present a case report and a review of the related literature. A 62-year-old man with SPS, latent autoimmune diabetes of the adult, and Graves-Basedow disease was referred to our medical center because of bilateral TAO. An ophthalmologic examination documented asymmetric bilateral NOSPECS (N = no signs or symptoms; O = only signs, no symptoms; S = soft tissue involvement; P = proptosis; E = extraocular muscle involvement; C = corneal involvement; and S = sight loss) class IV TAO (left eye>right eye) with a clinical activity score of 5 on a scale of 7. Magnetic resonance imaging of the orbits documented bilateral exophthalmos (left eye>right eye) due to retrobulbar fibroadipose infiltration, bilateral increase of extrinsic ocular muscle thickness, and enhancement of the left inferior rectus muscle on T2-weighted sequences. Because of concomitant incapacitating SPS and diet-controlled latent autoimmune diabetes of the adult, we excluded long-term corticosteroid therapy as an option and considered the use of rituximab, a mouse-human chimeric monoclonal antibody targeting the CD20 protein on pre-B and mature B lymphocytes. Rituximab was administered in accordance with the protocol for rheumatoid arthritis. During the subsequent 4 months, clinical signs and symptoms of TAO dramatically resolved (clinical activity score = 0 of 7) with a sustained improvement of the spastic paraparesis. The glutamic acid decarboxylase antibody titer remained high, and glycemic control and first-phase insulin secretion did not change. Treatment of active TAO with rituximab should be considered when standard intravenous pulse glucocorticoid treatment is contraindicated or ineffective and when SPS or other organ-specific autoimmune disorders with involvement of humoral autoimmunity are present, inasmuch as more than 1 disease may benefit from the use of this chimeric monoclonal antibody.

AB - To report the use of rituximab to treat thyroid-associated orbitopathy (TAO) in a patient with a concomitant B-cell organ-specific autoimmune disorder-the stiff person syndrome (SPS). We present a case report and a review of the related literature. A 62-year-old man with SPS, latent autoimmune diabetes of the adult, and Graves-Basedow disease was referred to our medical center because of bilateral TAO. An ophthalmologic examination documented asymmetric bilateral NOSPECS (N = no signs or symptoms; O = only signs, no symptoms; S = soft tissue involvement; P = proptosis; E = extraocular muscle involvement; C = corneal involvement; and S = sight loss) class IV TAO (left eye>right eye) with a clinical activity score of 5 on a scale of 7. Magnetic resonance imaging of the orbits documented bilateral exophthalmos (left eye>right eye) due to retrobulbar fibroadipose infiltration, bilateral increase of extrinsic ocular muscle thickness, and enhancement of the left inferior rectus muscle on T2-weighted sequences. Because of concomitant incapacitating SPS and diet-controlled latent autoimmune diabetes of the adult, we excluded long-term corticosteroid therapy as an option and considered the use of rituximab, a mouse-human chimeric monoclonal antibody targeting the CD20 protein on pre-B and mature B lymphocytes. Rituximab was administered in accordance with the protocol for rheumatoid arthritis. During the subsequent 4 months, clinical signs and symptoms of TAO dramatically resolved (clinical activity score = 0 of 7) with a sustained improvement of the spastic paraparesis. The glutamic acid decarboxylase antibody titer remained high, and glycemic control and first-phase insulin secretion did not change. Treatment of active TAO with rituximab should be considered when standard intravenous pulse glucocorticoid treatment is contraindicated or ineffective and when SPS or other organ-specific autoimmune disorders with involvement of humoral autoimmunity are present, inasmuch as more than 1 disease may benefit from the use of this chimeric monoclonal antibody.

UR - http://www.scopus.com/inward/record.url?scp=79952032750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952032750&partnerID=8YFLogxK

M3 - Article

C2 - 20350915

AN - SCOPUS:79952032750

VL - 16

SP - 677

EP - 685

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 4

ER -